Systematic Review of Levodopa Dose Equivalency Reporting in Parkinson's Disease

Claire L Tomlinson, Rebecca Stowe, Smitaa Patel, Caroline Rick, Richard Gray, Carl Clarke

Research output: Contribution to journalArticle

2340 Citations (Scopus)


Interpretation of clinical trials comparing different drug regimens for Parkinson's disease (PD) is complicated by the different dose intensities used: higher doses of levodopa and, possibly, other drugs produce better symptomatic control but more late complications. To address this problem, conversion factors have been calculated for antiparkinsonian drugs that yield a total daily levodopa equivalent dose (LED). LED estimates vary, so we undertook a systematic review of studies reporting LEDs to provide standardized formulae. Electronic database and hand searching of references identified 56 primary reports of LED estimates. Data were extracted and the mean and modal LEDs calculated. This yielded a standardized LED for each drug, providing a useful tool to express dose intensity of different antiparkinsonian drug regimens on a single scale. Using these conversion formulae to report LEDs would improve the consistency of reporting and assist the interpretation of clinical trials comparing different PD medications. © 2010 Movement Disorder Society.
Original languageEnglish
Pages (from-to)2649-2685
Number of pages37
JournalMovement Disorders
Issue number15
Publication statusPublished - 1 Jan 2010

Bibliographical note

C Smith is listed as C Tomlinson in the article.


  • treatment
  • Parkinson's disease
  • levodopa
  • levodopa equivalent dose


Dive into the research topics of 'Systematic Review of Levodopa Dose Equivalency Reporting in Parkinson's Disease'. Together they form a unique fingerprint.

Cite this